JP2020533969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533969A5 JP2020533969A5 JP2020511428A JP2020511428A JP2020533969A5 JP 2020533969 A5 JP2020533969 A5 JP 2020533969A5 JP 2020511428 A JP2020511428 A JP 2020511428A JP 2020511428 A JP2020511428 A JP 2020511428A JP 2020533969 A5 JP2020533969 A5 JP 2020533969A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- foxp3
- cell
- lentiviral
- host cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 30
- 210000004027 cell Anatomy 0.000 claims 17
- 239000002245 particle Substances 0.000 claims 8
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims 4
- 102000053917 human FOXP3 Human genes 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 210000000130 stem cell Anatomy 0.000 claims 4
- 108091029433 Conserved non-coding sequence Proteins 0.000 claims 3
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 3
- 102000044493 human CDCA4 Human genes 0.000 claims 3
- 239000012212 insulator Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108700004025 env Genes Proteins 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 206010071155 Autoimmune arthritis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 230000008938 immune dysregulation Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548891P | 2017-08-22 | 2017-08-22 | |
| US62/548,891 | 2017-08-22 | ||
| PCT/US2018/047586 WO2019040655A1 (en) | 2017-08-22 | 2018-08-22 | LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533969A JP2020533969A (ja) | 2020-11-26 |
| JP2020533969A5 true JP2020533969A5 (OSRAM) | 2021-09-30 |
| JP7290288B2 JP7290288B2 (ja) | 2023-06-13 |
Family
ID=65439627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511428A Active JP7290288B2 (ja) | 2017-08-22 | 2018-08-22 | 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でｆｏｘｐ３を発現するレンチウイルスベクター |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12060566B2 (OSRAM) |
| EP (1) | EP3672617A4 (OSRAM) |
| JP (1) | JP7290288B2 (OSRAM) |
| KR (1) | KR102780121B1 (OSRAM) |
| WO (1) | WO2019040655A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016427822B2 (en) | 2016-10-31 | 2025-01-23 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene |
| JP7290288B2 (ja) | 2017-08-22 | 2023-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でｆｏｘｐ３を発現するレンチウイルスベクター |
| CA3091491A1 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of human foxp3 in gene edited t cells |
| CA3091688A1 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of foxp3 in edited cd34+ cells |
| US20220168394A1 (en) * | 2019-04-23 | 2022-06-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing or restoring immune tolerance |
| CA3140910A1 (en) * | 2019-06-07 | 2020-12-10 | The Board Of Trustees Of The Leland Stanford Junior University | Foxp3 engineered cd4+ t cells for use in treg-based immunotherapy |
| WO2021028359A1 (en) * | 2019-08-09 | 2021-02-18 | Sangamo Therapeutics France | Controlled expression of chimeric antigen receptors in t cells |
| EP4410965A4 (en) * | 2021-09-27 | 2025-09-24 | Univ Kyoto | T LYMPHOCYTE PRODUCTION PROCESS |
| CN118946661A (zh) * | 2022-02-04 | 2024-11-12 | 国立大学法人京都大学 | T细胞生产方法 |
| WO2023182328A1 (ja) * | 2022-03-23 | 2023-09-28 | 国立大学法人京都大学 | 制御性ｔ細胞の製造方法 |
| KR20250077533A (ko) * | 2022-09-26 | 2025-05-30 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | T 세포 제조 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE405586T1 (de) | 2001-05-08 | 2008-09-15 | Darwin Molecular Corp | Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins |
| JP2004208548A (ja) | 2002-12-27 | 2004-07-29 | Institute Of Physical & Chemical Research | 免疫反応の抗原特異的抑制 |
| WO2008141282A2 (en) * | 2007-05-11 | 2008-11-20 | The Regents Of The University Of Michigan | Materials and methods for foxp3 tumor suppression |
| US20140065110A1 (en) * | 2012-08-31 | 2014-03-06 | The Regents Of The University Of California | Genetically modified msc and therapeutic methods |
| US9663564B2 (en) * | 2013-03-15 | 2017-05-30 | The Regents Of The University Of California | Vectors and methods to treat ischemia |
| WO2014121840A1 (en) | 2013-02-07 | 2014-08-14 | Medizinische Hochschule Hannover | Induced dendritic cells and uses thereof |
| GB201318347D0 (en) * | 2013-10-16 | 2013-11-27 | Ucl Business Plc | Retroviral vectors |
| KR102796744B1 (ko) | 2015-06-09 | 2025-04-15 | 에디타스 메디신, 인코포레이티드 | 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물 |
| JP7290288B2 (ja) * | 2017-08-22 | 2023-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でｆｏｘｐ３を発現するレンチウイルスベクター |
-
2018
- 2018-08-22 JP JP2020511428A patent/JP7290288B2/ja active Active
- 2018-08-22 US US16/640,306 patent/US12060566B2/en active Active
- 2018-08-22 KR KR1020207008314A patent/KR102780121B1/ko active Active
- 2018-08-22 EP EP18848409.1A patent/EP3672617A4/en active Pending
- 2018-08-22 WO PCT/US2018/047586 patent/WO2019040655A1/en not_active Ceased
-
2024
- 2024-06-26 US US18/754,883 patent/US20240336935A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wolff et al. | Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years | |
| Vannucci et al. | Viral vectors: a look back and ahead on gene transfer technology | |
| Morizono et al. | Multilineage cells from adipose tissue as gene delivery vehicles | |
| JP7290288B2 (ja) | 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でｆｏｘｐ３を発現するレンチウイルスベクター | |
| RU2014117201A (ru) | ЛЕНТИВИРУСНЫЕ ВЕКТОРЫ, ПСЕВДОТИПИРОВАННЫЕ МУТАНТНЫМИ BaEV | |
| Galimi et al. | Opportunities for the use of lentiviral vectors in human gene therapy | |
| JP2020010684A5 (OSRAM) | ||
| WO2009013324A9 (en) | Vector particles for targeting cd34+ cells | |
| EP3191596A1 (en) | Lentiviral vector for treating hemoglobin disorders | |
| Freitas et al. | Protection is not always a good thing: the immune system’s impact on gene therapy | |
| Lundstrom | Gene therapy applications of viral vectors | |
| Bell Jr et al. | RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors | |
| JP2023544633A (ja) | 治療における使用のためのｒａｇ１の置き換え | |
| Curran et al. | Nonprimate lentiviral vectors | |
| Bergmann et al. | Progress and problems with viral vectors for delivery of talens | |
| RU2006123079A (ru) | Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы | |
| MIYAKE et al. | Two-step gene transfer using an adenoviral vector carrying the CD4 gene and human immunodeficiency viral vectors | |
| Miyake et al. | Selective killing of human immunodeficiency virus-infected cells by targeted gene transfer and inducible gene expression using a recombinant human immunodeficiency virus vector | |
| CN116635523A (zh) | 用于疗法中的rag1的替代物 | |
| Dalberto et al. | Mesenchymal stem cells as a platform for gene therapy protocols | |
| Shunchang et al. | Expression of truncated dystrophin cDNAs mediated by a lentiviral vector | |
| Counsell et al. | 527. Exploiting Retroviral Recombination for the Delivery of Full-Length Dystrophin cDNA | |
| JP2024538769A (ja) | Ｒａｇ１遺伝子における突然変異を修正するのに有用なポリヌクレオチド | |
| US20230040417A1 (en) | Defective interfering particles | |
| Rahmeh et al. | Cell type-specific adaptation of the SARS-CoV-2 spike |